We want to transform healthcare by developing novel vaccines that are lifesaving and improving quality of life around the world.
We are a clinical-stage biotechnology company listed on NASDAQ First North Growth Market Sweden with a resolute vision of the future:
Developing innovative vaccines for a healthier world
Advancing groundbreaking vaccines through our exclusive technological platform
By leveraging our proprietary ExpreS2 protein expression system, we are playing a key role in the development of cutting-edge vaccines to address some of the worst and most impactful diseases.
Our vaccine candidates aim at bringing hope to millions by preventing infectious diseases and treating cancer, saving lives, and fostering resilient communities.
Latest news
ExpreS2ion to present in upcoming investor and scientific events
Hørsholm, Denmark, 31 October2024 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in upcoming investor and scientific events, including BIO-Europe, the Protein & Antibody Engineering Summit Europe, a 2024 Third Quarter Results Webinar, and the LSX Investival Showcase.
Read moreThe Board of Directors of ExpreS2ion Biotech Holding AB (publ) has resolved on the record date for the reverse share split
Hørsholm, Denmark, 24 October 2024 - At the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") on 21 October 2024, it was resolved on a reverse share split of the Company's shares, whereby forty (40) existing shares shall be consolidated into one (1) share (Sw. sammanläggning 1:40). The Board of…
Read moreBulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB (publ)
Today, on 21 October 2024, ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") has held an Extraordinary General Meeting 2024 (the "EGM"). Notice of the EGM and complete proposals for resolutions taken are available on the Company's investor website, https://investor.expres2ionbio.com.
Read more